Detalhe da pesquisa
1.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Lancet Oncol
; 19(5): 649-659, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29650362
2.
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP.
Genes Dev
; 24(13): 1403-17, 2010 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20595232
3.
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Nat Chem Biol
; 11(6): 432-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915199
4.
Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652.
Drug Metab Dispos
; 43(7): 936-43, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25887455
5.
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination.
NAR Cancer
; 5(3): zcad039, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37519629
6.
Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.
Endocr Rev
; 29(7): 898-938, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18815314
7.
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity.
SLAS Discov
; 25(4): 361-371, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31585521
8.
Mice lacking Pctp /StarD2 exhibit increased adaptive thermogenesis and enlarged mitochondria in brown adipose tissue.
J Lipid Res
; 50(11): 2212-21, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19502644
9.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell
; 36(1): 100-114.e25, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257072
10.
RNA-modifying proteins as anticancer drug targets.
Nat Rev Drug Discov
; 17(6): 435-453, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773918
11.
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
PLoS One
; 13(6): e0197372, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29856759
12.
Drug Discovery and Chemical Biology of Cancer Epigenetics.
Cell Chem Biol
; 24(9): 1120-1147, 2017 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28938089
13.
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
Mol Cancer Ther
; 16(5): 850-860, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28292935
14.
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.
Mol Cancer Ther
; 16(11): 2586-2597, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28835384
15.
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.
Cancer Cell
; 31(2): 286-299, 2017 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28196596
16.
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
PLoS One
; 12(1): e0170539, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28085948
17.
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.
Sci Rep
; 7(1): 17993, 2017 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29269946
18.
Structural Insights into Ternary Complex Formation of Human CARM1 with Various Substrates.
ACS Chem Biol
; 11(3): 763-71, 2016 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26551522
19.
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
PLoS One
; 11(7): e0158888, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27391784
20.
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound.
ACS Med Chem Lett
; 6(6): 655-9, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26101569